N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Hubertus Hautzel - , University of Duisburg-Essen (Author)
  • Yazan Alnajdawi - , University Hospital Essen, University of Duisburg-Essen (Author)
  • Wolfgang P. Fendler - , University of Duisburg-Essen (Author)
  • Christoph Rischpler - , University of Duisburg-Essen (Author)
  • Kaid Darwiche - , University Hospital Essen, University of Duisburg-Essen (Author)
  • Wilfried E. Eberhardt - , University of Duisburg-Essen, University Hospital Essen (Author)
  • Lale Umutlu - , University of Duisburg-Essen (Author)
  • Dirk Theegarten - , University of Duisburg-Essen (Author)
  • Martin Stuschke - , University of Duisburg-Essen (Author)
  • Martin Schuler - , University of Duisburg-Essen, University Hospital Essen (Author)
  • Clemens Aigner - , University Hospital Essen, University of Duisburg-Essen (Author)
  • Ken Herrmann - , University of Duisburg-Essen (Author)
  • Till Plönes - , University Hospital Essen, University of Duisburg-Essen, German Cancer Consortium (DKTK) partner site Essen / Düsseldorf (Author)

Abstract

Background: Large cell neuroendocrine carcinoma of the lung (LCNEC) is a rare entity occurring in less than 4% of all lung cancers. Due to its low differentiation and high glucose transporter 1 (GLUT1) expression, LCNEC demonstrates an increased glucose turnover. Thus, PET/CT with 2-[18F]-fluoro-deoxyglucose ([18F]FDG) is suitable for LCNEC staging. Surgery with curative intent is the treatment of choice in early stage LCNEC. Prerequisite for this is correct lymph node staging. This study aimed at evaluating the diagnostic performance of [18F]FDG PET/CT validated by histopathology following surgical resection or mediastinoscopy. N-staging interrater-reliability was assessed to test for robustness of the [18F]FDG PET/CT findings. Methods: Between 03/2014 and 12/2020, 46 patients with LCNEC were included in this single center retrospective analysis. All underwent [18F]FDG PET/CT for pre-operative staging and subsequently either surgery (n = 38) or mediastinoscopy (n = 8). Regarding the lymph node involvement, sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) were calculated for [18F]FDG PET/CT using the final histopathological N-staging (pN0 to pN3) as reference. Results: Per patient 14 ± 7 (range 4–32) lymph nodes were resected and histologically processed. 31/46 patients had no LCNEC spread into the lymph nodes. In 8/46 patients, the final stage was pN1, in 5/46 pN2 and in 2/46 pN3. [18F]FDG PET/CT diagnosed lymph node metastasis of LCNEC with a sensitivity of 93%, a specificity of 87%, an accuracy of 89%, a PPV of 78% and a NPV of 96%. In the four false positive cases, the [18F]FDG uptake of the lymph nodes was 33 to 67% less in comparison with that of the respective LCNEC primary. Interrater-reliability was high with a strong level of agreement (κ = 0.82). Conclusions: In LCNEC N-staging with [18F]FDG PET/CT demonstrates both high sensitivity and specificity, an excellent NPV but a slightly reduced PPV. Accordingly, preoperative invasive mediastinal staging may be omitted in cases with cN0 disease by [18F]FDG PET/CT. In [18F]FDG PET/CT cN1-cN3 stages histological confirmation is warranted, particularly in case of only moderate [18F]FDG uptake as compared to the LCNEC primary.

Details

Original languageEnglish
Article number68
JournalEJNMMI research
Volume11
Issue number1
Publication statusPublished - 2021
Peer-reviewedYes
Externally publishedYes

Keywords

Sustainable Development Goals

Keywords

  • Large cell neuroendocrine carcinoma, Lung, Nodal staging, PET/CT, [F]FDG